文献速递呼吸危重症与机械通气呼吸道感染

免疫功能低下急性呼吸衰竭危重患者:单纯高流量氧疗与交替无创通气的随机对照试验

High-flow nasal oxygen alone or alternating with non-invasive ventilation in critically ill immunocompromised patients with acute respiratory failure: a randomised controlled trial.
PubMed 文献 · Lancet Respir Med · 2022-03-21

FLORALI-IM 多中心开放标签随机试验纳入 299 例免疫功能低下合并急性呼吸衰竭的 ICU 患者,比较单纯经鼻高流量氧疗(HFNO)与 HFNO 交替无创通气(NIV)。

要点

  • 免疫功能低下急性呼吸衰竭患者中,单纯 HFNO 与 HFNO 交替 NIV 的第 28 天死亡率无差异。
  • 研究把握度有限,结果需谨慎解释,不能据此排除 NIV 的潜在获益或危害。

核心结论

  • 在免疫功能低下合并急性呼吸衰竭的危重患者中,单纯 HFNO 与 HFNO 交替 NIV 的第 28 天死亡率无差异。
  • 因研究把握度有限,结果应谨慎解释。

研究设计与样本

  • FLORALI-IM 为多中心、开放标签、随机对照试验,在 29 个 ICU(法国 28 个、意大利 1 个)开展。
  • 纳入成人免疫功能低下合并急性呼吸衰竭患者,定义为呼吸频率≥25 次/分且动脉血氧分压/吸入氧浓度比≤300 mm Hg。
  • 2017 年 1 月 21 日至 2019 年 3 月 4 日,497 例合格患者中 300 例随机分配,1 例撤回知情同意,最终 299 例纳入意向性分析(HFNO 组 154 例,NIV 组 145 例)。
  • 主要结局为第 28 天死亡率,在意向性分析人群中评估。

关键数值与推荐

  • 急性呼吸衰竭定义:呼吸频率≥25 次/分且 PaO2/FiO2≤300 mm Hg。
  • HFNO 组:持续 HFNO,气体流量 60 L/min 或最高耐受流量。
  • NIV 组:首 session 至少 4 小时,之后每日至少 12 小时,目标潮气量低于预测体重 8 mL/kg,呼气末正压至少 8 cm H2O,NIV 间期给予 HFNO。
  • 关键排除标准包括:严重高碳酸血症(PaCO2>50 mm Hg)、可从 NIV 强烈获益者(慢性肺病、心源性肺水肿或术后)、严重休克、意识障碍(GCS≤12)、紧急插管需求、不插管医嘱及 NIV 禁忌。

临床怎么用

  • 对于免疫功能低下合并急性呼吸衰竭的危重患者,单纯 HFNO 可作为 HFNO 交替 NIV 策略的替代选择之一。
  • 临床决策时需结合患者耐受性与不适感,HFNO 启动后不适感可能更轻。
  • 因研究把握度有限,不应据此完全否定 NIV 在特定患者中的潜在作用。

局限性

  • 研究把握度有限,结果需谨慎解释。
  • 开放标签设计可能影响主观结局(如不适感)的评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although non-invasive ventilation (NIV) is recommended for immunocompromised patients with acute respiratory failure in the intensive care unit (ICU), it might have deleterious effects in the most severe patients. High-flow nasal oxygen (HFNO) alone might be an alternative method to reduce mortality. We aimed to determine whether HFNO alone could reduce the rate of mortality at day 28 compared with HFNO alternated with NIV. METHODS: FLORALI-IM is a multicentre, open-label, randomised clinical trial conducted in 29 ICUs (28 in France and one in Italy). Adult immunocompromised patients with acute respiratory failure, defined as respiratory rate of 25 breaths per min or more and a partial pressure of arterial oxygen to inspired fraction of oxygen ratio of 300 mm Hg or lower, were randomly assigned (1:1) to HFNO alone (HFNO alone group) or NIV alternating with HFNO (NIV group). Key exclusion criteria were severe hypercapnia above 50 mm Hg, patients who could strongly benefit from NIV (ie, those with underlying chronic lung disease, with cardiogenic pulmonary oedema, or who were postoperative), severe shock, impaired consciousness defined as Glasgow coma score ≤12, urgent need for intubation, do not intubate order, and contraindication to NIV. Patients were assigned using computer-generated permuted blocks and were stratified according to centre and to the type of immunosuppression using a centralised web-based management system. In the HFNO alone group, patients were continuously treated by HFNO with a gas flow rate of 60 L/min or the highest tolerated. In the NIV group, patients were treated with NIV with a first session of at least 4 h, and then by sessions for a minimal duration of 12 h a day, with a dedicated ventilator, targeting a tidal volume below 8 mL/kg of predicted bodyweight, and with a positive end-expiratory level of at least 8 cm H2O. NIV sessions were interspaced with HFNO delivered as in the HFNO alone group. The primary outcome was mortality at day 28 and was assessed in the intention-to-treat population. Secondary outcomes were mortality in the ICU, in hospital, at day 90 and at day 180, intubation at day 28, length of stay in the ICU and in hospital, number of ventilator-free days at day 28, number of oxygenation technique-free days at day 28, and efficacy and tolerance of oxygenation techniques. The trial is registered with ClinicalTrials.gov, NCT02978300, and is complete. FINDINGS: Between Jan 21, 2017 to March 4, 2019, of 497 eligible patients, 300 were randomly assigned but one patient withdrew consent, leaving 299 patients included in the intention-to-treat analysis (154 assigned to the HFNO alone group and 145 assigned to NIV group). Mortality rate at day 28 was 36% (95% CI 29·2 to 44·2; 56 of 154 patients) in the HFNO alone group and 35% (27·9 to 43·2; 51 of 145 patients) in the NIV group (absolute difference 1·2% [95% CI -9·6 to 11·9]; p=0·83). None of the other prespecified secondary outcomes were different between groups except for greater decreased discomfort after initiation of HFNO than with NIV (-4 mm on visual analogic scale [IQR -18 to 4] vs 0 mm [-16 to 17]; p=0·040). INTERPRETATION: In critically ill immunocompromised patients with acute respiratory failure, the mortality rate did not differ between HFNO alone and NIV alternating with HFNO. However, study power was limited, so results should be interpreted with caution. FUNDING: French Ministry of Health.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Coudroy R, Frat JP, Ehrmann S, et al. High-flow nasal oxygen alone or alternating with non-invasive ventilation in critically ill immunocompromised patients with acute respiratory failure: a randomised controlled trial. Lancet Respir Med. 2022. PMID: 35325620. doi:10.1016/S2213-2600(22)00096-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。